Comparison of ultrasound guided injection of botulinum toxin at the origin of plantar fasciitis with injection of botulinum toxin by Babcock method in the treatment of plantar fasciitis

Start Date23 Sep 2023

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

JPRN-jRCT1090220265

/ RecruitingNot ApplicableIIT

The study for the effect of botulinum toxin for upper limb spasticity - The effect of botulinum toxin for upper limb spasticity

Start Date24 Nov 2016

Sponsor / Collaborator

Higuchi, Inc.

100 Clinical Results associated with Botulinum toxin(UroGen Pharma Ltd.)

100 Translational Medicine associated with Botulinum toxin(UroGen Pharma Ltd.)

100 Patents (Medical) associated with Botulinum toxin(UroGen Pharma Ltd.)

3,671

Literatures (Medical) associated with Botulinum toxin(UroGen Pharma Ltd.)

01 Dec 2025·Techniques in Coloproctology

Urge fecal incontinence: are intramural rectal injections of botulinum toxin a long-term treatment option?

Article

Author: Baumstarck, Karine ; Vitton, Véronique ; Onana Ndong, Philippe

BACKGROUND AND AIMS:

Unsuccessful first-line conservative treatments for managing fecal incontinence (FI) lead to considering predominantly invasive options, posing challenges in terms of cost and patient acceptance of benefit/risk ratio. Recent data from a prospective randomized study have highlighted intramural rectal botulinum toxin (BoNT/A) injection as a promising minimally invasive alternative for urge FI, demonstrating efficacy at 3 months but lacking long-term evidence. This study aimed to evaluate the sustained efficacy and injection frequency of intramural rectal BoNT/A injection in the treatment of urge FI.

METHODS:

This retrospective monocentric study enrolled all patients who underwent intramural rectal BoNT/A injection for urge FI after failed conservative therapy or sacral neuromodulation (SNM). Injections were administered during sigmoidoscopy, delivering 200 U of BoNT/A at 10 circumferentially distributed sites. Treatment effectiveness was assessed using the Cleveland clinic incontinence score (CCS) and a visual analog scale (VAS) to measure the severity of discomfort related to episodes of fecal urgency, with reinjection performed upon symptom recurrence.

RESULTS:

In total, 41 patients (34 females) were included, with a median follow-up of 24.9 (range 3.2-70.3) months. Overall, 11 patients had previously failed sacral nerve stimulation. Significant reductions were observed in the CCS (median 11 versus 7, p = 0.001) and VAS symptoms (median 4, range 0-5 versus median 2, range 0-5, p = 0.001). In total, 22 patients (53%) experienced a reduction in the CCS by over 50%. The median interval between intramural rectal BoNT/A injections was 9.8 months (range 5.3-47.9 months).

CONCLUSIONS:

This study provides the first evidence of the sustained efficacy of intramural rectal BoNT/A injection for urge FI. Further investigations are warranted to refine patient selection and reinjection criteria, evaluate socioeconomic impacts, and compare rectal BoNT/A injection with other therapeutic modalities.

01 Jul 2025·NEUROCHIRURGIE

Comprehensive pain management in spinal surgery: The role of botulinum toxin

Letter

Author: Sophie, Galmiche ; Pierre-Jacques, Finiels ; Marie, De Boutray ; Dominique, Batifol

The use of botulinum toxin in pre- and post-operative management of pain in spinal surgery is described, following a specific administration protocol. The initial encouraging results (particularly the absence of opioid use in the post-operative period) support the potential role of BoNT-A (Botulinum Neurotoxin type A) as a targeted therapeutic option in this specific clinical setting.

01 Jun 2025·TOXICON

Effects of botulinum toxin on pain control mechanisms, muscle structure and cortical reorganization, a mini-review

Article

Author: Mollaei, Zahra ; Mehraban Jahromi, Mostafa ; Grünerová Lippertová, Marcela ; Vlček, Přemysl

Spasticity often results in significant disability, which complicates rehabilitation and daily activities. This review explores the role of botulinum toxin type A (BoNT-A) in the treatment of spasticity, focusing on its effects on muscle structure and activity, function, cortical reorganization, and pain. Our findings indicate that BoNT-A injections improve motor function and gait, particularly in stroke patients, by reducing abnormal muscle activity and enhancing postural control. However, BoNT-A may also induce unwanted biomechanical changes, such as muscle atrophy and alterations in contractile elements, which could impact long-term muscle function. Regarding pain management in spasticity, BoNT-A has shown promise by reducing both peripheral and central sensitization mechanisms. Additionally, BoNT-A influences the central nervous system (CNS) by inducing cortical reorganization, which may further contribute to clinical improvements. Lastly, BoNT-A treatment requires careful consideration of individual patient characteristics to optimize outcomes and minimize side effects. A multidisciplinary approach that combines BoNT-A with physical therapy is essential to maximize functional recovery and improve the quality of life in patients with spasticity.

News (Medical) associated with Botulinum toxin(UroGen Pharma Ltd.)

21 Nov 2024

·www.medicaldesignandoutsourcing.com

Merz Therapeutics and S3 Connected Health launch iFlexo

NEWS RELEASE: Merz Therapeutics and S3 Connected Health Pioneer New Digital Health Solution, iFlexo, for People Living with Post-Stroke Spasticity Dublin/Frankfurt — Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing rehabilitation for people with post-stroke spasticity as part of its ongoing commitment to supporting stroke survivors. The app, developed in collaboration with S3 Connected Health, provides targeted exercises and rehabilitation programs specifically aimed at improving mobility for those with mild to moderate spasticity. By offering guided routines, iFlexo aims to help stroke survivors regain independence and improve their overall quality of life. Merz Therapeutics is the first and only neurotoxins pharmaceutical company to offer a platform to support self-rehabilitation. iFlexo, developed and operated on S3 Connected Health’s digital health platform Affinial, was released in August 2024 and is available for iOS and Android in France. Developing iFlexo on Affinial enabled the creation of a differentiated user experience optimized for post-stroke patients. An accelerated time to market of just five months was achieved thanks to Affinial’s range of pre-built, customizable digital health services. The Affinial platform enables iFlexo to scale and evolve by addressing current and future compliance, legal, cybersecurity, and regulatory requirements. During the pilot stage in France, it gained significant interest from patients, clinicians, and key opinion leaders. Dr. Alexandre Bertholon, Physical Medicine & Rehabilitation at Le Clos Champirol, says: “iFlexo is a promising solution in physical rehabilitation, offering a much-needed response to the current challenges in the field. It enables patients to engage in self-rehabilitation at home, focusing on their personal goals. This platform not only supports patients but also enhances efficiency for healthcare professionals by optimizing and extending the results of rehabilitation. It demonstrates how new solutions can improve patient outcomes and make care more effective.” Up to one-third of stroke survivors experience spasticity, a condition that can severely limit their ability to perform everyday tasks, often leaving them reliant on others.[1] For these individuals, personalized botulinum neurotoxin injection therapy as part of a multimodal approach can improve muscle tone and consequently patient’s mobility and quality of life. [2] Merz Therapeutics and S3 Connected Health are committed to providing better outcomes for more patients and are currently working on expanding the solution to more countries, starting in the coming months. [1] Ali, A., McCarthy, A.D., Reeves, M. et al. Sheffield Adaptive Patterned Electrical Stimulation (SHAPES) Therapy for Post Stroke Arm spasticity: study protocol for a 3-arm, a partially blinded, randomised controlled trial. BMC Neurol 24, 437 (2024). [2] Otero-Luis I, Martinez-Rodrigo A, Cavero-Redondo I, Moreno-Herráiz N, Martínez-García I, Saz-Lara A. Effect of Botulinum Toxin Injections in the Treatment of Spasticity of Different Etiologies: An Umbrella Review. Pharmaceuticals. 2024; 17(3):310. Merz Therapeutics Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs. For more information, please visit: S3 Connected Health S3 Connected Health is the specialist digital health partner for life science companies, developing regulated digital health solutions that improve the lives of people with acute and chronic conditions. It has delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. The company’s scalable and secure solutions improve disease management, differentiate pharmaceutical products and deliver new therapeutic approaches. Affinial, S3 Connected Health’s digital health platform, offers partners the opportunity to develop customized digital health solutions tailored to specific patient, device or disease needs. The platform’s pre-built services provide best practice implementation to ensure successful solution adoption and an accelerated time-to-market. For more information, please visit: The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.

21 May 2024

·www.prnewswire.com

Guidance for Common Post-stroke Condition of Spasticity Released by the American Academy of Physical Medicine and Rehabilitation

ROSEMONT, Ill., May 21, 2024 /PRNewswire/ -- The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has today released spasticity guidance to establish a framework that reviews treatment options, endorses the highest quality of evidence-based care, and encourages research where there are knowledge gaps. Spasticity is a group of symptoms characterized by muscle tightening or reduced stretchability following injuries to or conditions affecting the brain and spinal cord, including stroke, cerebral palsy, multiple sclerosis, traumatic brain injury, or spinal cord injuries. Continue Reading When spasticity symptoms are recognized early, physicians can better manage and treat it through a range of therapies. Post this Spasticity symptoms include uncontrollable rhythmic, shaking movements, cramping, spasms, and tight, rigid muscles that cannot be stretched easily and may cause pain. Other symptoms may include incoordination, fatigue, weakness, and impaired motor control. Spasticity is often delayed and an evolving condition. If left untreated, spasticity can cause muscles to become stuck, leading to joint deformity. "Physicians have a growing toolbox of treatments for spasticity," said guidance author Dr. Preeti Raghavan, MBBS. "When patients or their caregivers recognize the symptoms of spasticity and seek treatment for those symptoms, we have even better chances to manage and treat their spasticity symptoms through a range of therapies." The first line of treatment and management interventions aimed at reducing the effects of spasticity is rehabilitative therapy. Simple, non-pharmacologic interventions that facilitate movement and improve function should be attempted before resorting to treatments that carry more risks and side effects. Therapeutic interventions can be used individually or in combination, including oral medications, injectables such as Botulinum toxin, and surgical options. An integrated, multi-disciplinary, goal-centered management approach is essential to providing long-term, comprehensive care for spasticity. PM&R physicians are leaders in recovery and regularly care for patients with conditions that cause spasticity, such as rehabilitating patients post-stroke or other conditions causing spasticity. Because of this, PM&R physicians have the necessary specialized equipment, supplies, and prior authorization procedures in place to treat spasticity patients and work with their insurance providers. The guidance is published in the PM&R Journal. The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians specializing in physical medicine and rehabilitation. PM&R physicians, also known as physiatrists, treat a wide variety of medical conditions affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles and tendons. PM&R physicians evaluate and treat injuries, illnesses and disability and are experts in designing comprehensive, patient-centered treatment plans. Physiatrists utilize cutting-edge as well as time-tested treatments to maximize function and quality of life. SOURCE American Academy of Physical Medicine and Rehabilitation

09 Jan 2024

·www.prnewswire.com

AMERICAN ACADEMY OF DERMATOLOGY: START THE NEW YEAR OFF WITH A FRESH START (AND SKIN)

Advice from a board-certified dermatologist on seeking cosmetic treatments ROSEMONT, Ill., Jan. 9, 2024 /PRNewswire/ -- With a rise in both public accessibility and visibility, cosmetic treatments are more popular than ever. Whether your New Year's resolution is to improve your health or to look and feel your best, the most important thing to remember is that your results depend largely on the skills and knowledge of the person performing your treatment. "There is no one-size-fits-all or 'cookie cutter' approach to combat the signs of aging because aging looks different on everyone. On the flipside, there is no one cosmetic treatment to address all of these changes," said Lauren Fine, MD, FAAD, a board-certified dermatologist in Chicago. "The best cosmetic outcomes are often achieved with a comprehensive approach, starting with skincare at home, combined with other in-office treatments recommended by a board-certified dermatologist that is taking all of these factors into account when recommending a cosmetic treatment that is best for you." While over-the-counter options are available, they may not be able to provide the results that a cosmetic procedure can deliver. Common treatment options include botulinum toxin, fillers, and lasers. Botulinum toxin is used to diminish signs of aging, including frown lines between the eyebrows and crow's feet, as well as for hyperhidrosis (excessive sweating). Most people see results within 3 to 7 days and results can last about 3 to 4 months—even longer when treating excessive sweating. Fillers are also used to diminish signs of aging by restoring lost fullness to the face, lips, and hands, as well as to lessen scars and erase fine lines. Most fillers provide immediate results; however, they tend to be temporary and require repeat treatments. Lasers can treat a variety of concerns including stretch marks, scars, the removal of unwanted hair, and age spots. It is important to note that lasers cannot fully remove stretch marks or scars, but rather make them less noticeable. Multiple sessions are often necessary to see results when undergoing this form of treatment. Before undergoing any cosmetic procedure, Dr. Fine and the AAD recommend asking the following questions: What are the doctor's credentials and are they board-certified? Remember, dermatologists are physicians with extensive education, training, and experience in keeping the skin, hair, and nails healthy. How many of these particular cosmetic surgery procedures has the physician performed? The procedure should be one that the doctor performs regularly. Ask to see before-and-after photos of previous patients. What result can I expect and are there any risks? Because your results depend largely on the skill and experience of the person performing the procedure, it is important to select a board-certified physician. A dermatologist can tell you if the procedure will deliver the desired results, based on the condition of your skin as well as your age and health. If you have specific cosmetic concerns or questions about a particular treatment, the best place to start is with a board-certified dermatologist. "While some cosmetic procedures may look easy to perform, understanding how to safely treat patients and deliver the best desired result requires an in-depth medical knowledge of the skin," shared Dr. Fine. "In the age of social media and information overload, anyone can tout themselves as an expert. Going to a board-certified dermatologist for cosmetic treatments ensures that you will receive effective results from an expert with a deep understanding of the skin." If you're considering a cosmetic procedure, visit aad.org/findaderm to find a board-certified dermatologist in your area. More Information Cosmetic treatments Cosmetic treatment safety AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology

100 Deals associated with Botulinum toxin(UroGen Pharma Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Botulinum toxin(UroGen Pharma Ltd.)	M03AX01	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Incontinence	Phase 2	Israel	UroGen Pharma Ltd.	01 Oct 2016
Urinary Bladder, Overactive	Phase 2	Israel	UroGen Pharma Ltd.	01 Oct 2016
Cystitis, Interstitial	Phase 2	-	Allergan UC	-
Cystitis, Interstitial	Phase 2	-	UroGen Pharma Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


APAO2024	Not Applicable	Esotropia	29	Botulinum Toxin Injection	rxskqqzzep(smhxnaudsa) = rultqhllrr rhmavodtkg (pqykudvkml, 5.4) View more	Positive	22 Feb 2024
APAO2024	Not Applicable	Graves Ophthalmopathy	-	Botulinum Toxin A injection	vjzzykgtyt(brlpvrtnee) = iebalidlog ykqsjjnfhs (vwtojxyqmw ) View more	-	22 Feb 2024
APAO2024	Not Applicable	Esotropia	68	Bimedial recti toxin injections	epxfjqbmcu(optyfxkozs) = qvvvsxlclx duspnxilrh (xwfwrqweyd )	Positive	22 Feb 2024
APAO2024	Not Applicable	Esotropia	68	Botulinum Toxin (Strabismus surgery)	gqpuxeifbe(reqvauxkyf) = qqcfmooaue cdmpbbxbxr (dshtnmuwgx ) View more	Positive	22 Feb 2024
EADV2023	Not Applicable	-	44	Botulinum toxin	sbcdhigykw(serfpitiwl) = intense pain during ( 2 ) or after ( 3, transitory ) infiltration and transitory decrease in manual strength ( 3 ) ixienxkrgd (demdqjlduq ) View more	Positive	11 Oct 2023
CNS2023	Not Applicable	Cerebral Palsy	-	botulinum toxin	kxfleyrptx(hqlxyyleuf) = maoykrnfcd pjnobufzoh (rsgrogqrfz ) View more	-	01 Oct 2023
CNS2023	Not Applicable	Cerebral Palsy	-	botulinum toxin	kxfleyrptx(hqlxyyleuf) = fcehdovbob pjnobufzoh (rsgrogqrfz ) View more	-	01 Oct 2023
MDS2023	Not Applicable	Dystonic Disorders	-	Botulinum toxin	pjylqluvgr(vcqpmjbrvf) = in four patients ihwqsjpvoh (lgssqcnlnc ) View more	-	27 Aug 2023
MDS2023	Not Applicable	Dystonia	578	botulinum toxin	stljayvpxj(esnrnztvwy) = eiwsycjdct npujxzoedz (ochcmquqfu ) View more	Positive	27 Aug 2023
MDS2023	Not Applicable	Dystonia	578	botulinum toxin	puetctfivy(lazkiwgbsm) = qpvkvelqbt djunyaueeu (crfenczrjx )	Positive	27 Aug 2023
P11-12.007 (AAN2023)	Not Applicable	Trigeminal Neuralgia	5	Botulinum toxin type A	widvmdcybq(wmdjrqfzuc) = seen only in 1 patient after the first injection getocqyzdq (hlvetdwfxb )	Positive	25 Apr 2023
P11-11.007 (AAN2023)	Not Applicable	Hemifacial Spasm \| Blepharospasm	152	Preseptal Botulinum Toxin Injection	pedtwpgmkh(vffpkvlyoj) = jfsgbygiqz rgiattwtna (qocqcnmiid )	Positive	25 Apr 2023
P11-11.007 (AAN2023)	Not Applicable	Hemifacial Spasm \| Blepharospasm	152	Pretarsal Botulinum Toxin Injection	pedtwpgmkh(vffpkvlyoj) = cycafsrdsv rgiattwtna (qocqcnmiid )	Positive	25 Apr 2023
AAD2023	Not Applicable	Primary Axilary Hyperhidrosis	10	Botulinum toxin-loaded detachable dissolvable microneedles (BoNT-MNs)	gqgaixokro(ausskdhvnq) = ufamyuxtje eqnmvpqrmy (dxtmfwaivl )	-	17 Mar 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Botulinum toxin(UroGen Pharma Ltd.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation